{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T20:46:54Z","timestamp":1771879614593,"version":"3.50.1"},"reference-count":20,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2002,8,15]]},"abstract":"<jats:p>PURPOSE: To compare the efficacy and tolerability of fulvestrant (formerly ICI 182,780) and anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.<\/jats:p><jats:p>PATIENTS AND METHODS: Patients (n = 451) with advanced breast cancer were randomized to receive fulvestrant 250 mg as a once-monthly (one \u00d7 5 mL) intramuscular injection or an oral dose of anastrozole 1 mg in this open, parallel-group, multicenter trial. The primary end point was time to progression (TTP). Secondary end points included objective response (OR) rates, defined as complete response (CR) or partial response (PR), duration of response (DOR), and tolerability.<\/jats:p><jats:p>RESULTS: Patients were followed for a median period of 14.4 months. In terms of TTP, fulvestrant was as effective as anastrozole (hazard ratio, 0.98; confidence interval [CI], 0.80 to 1.21; P = .84). Median TTP was 5.5 months for fulvestrant and 5.1 months for anastrozole. OR rates showed a numerical advantage for fulvestrant (20.7%) over anastrozole (15.7%) (odds ratio, 1.38; CI, 0.84 to 2.29; P = .20). Clinical benefit rates (CR + PR + stable disease \u2265 24 weeks) were 44.6% for fulvestrant and 45.0% for anastrozole. Median DOR was 15.0 months for fulvestrant and 14.5 months for anastrozole. Both treatments were well tolerated, with 3.2% and 1.3% of fulvestrant- and anastrozole-treated patients, respectively, withdrawn from treatment because of an adverse event.<\/jats:p><jats:p>CONCLUSION: Fulvestrant was as effective as anastrozole. These data confirm that fulvestrant is an additional, effective, and well-tolerated treatment for advanced breast cancer in postmenopausal women whose disease progressed on prior endocrine therapy.<\/jats:p>","DOI":"10.1200\/jco.2002.10.057","type":"journal-article","created":{"date-parts":[[2002,10,1]],"date-time":"2002-10-01T21:58:26Z","timestamp":1033509506000},"page":"3396-3403","source":"Crossref","is-referenced-by-count":533,"title":["Fulvestrant, Formerly ICI 182,780, Is as Effective as Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing After Prior Endocrine Treatment"],"prefix":"10.1200","volume":"20","author":[{"given":"A.","family":"Howell","sequence":"first","affiliation":[{"name":"From the Christie Hospital, Manchester, City Hospital, Nottingham, and AstraZeneca, Macclesfield, Cheshire, United Kingdom; Instituto Portugues De Oncologia De Coimbra, Coimbra, Portugal; Odborny Lecebny Ustav Onkologie A Pneumologie, Nova Ves Plod Plesi, Czech Republic; Institut Bergonie, Bordeaux, France; Haematologisch\/Onkologische Praxis, Hamburg, Germany; University Hospital Leuven, Leuven, Belgium; and Norwegian Radium Hospital, Oslo, Norway."}]},{"given":"J.F.R.","family":"Robertson","sequence":"additional","affiliation":[{"name":"From the Christie Hospital, Manchester, City Hospital, Nottingham, and AstraZeneca, Macclesfield, Cheshire, United Kingdom; Instituto Portugues De Oncologia De Coimbra, Coimbra, Portugal; Odborny Lecebny Ustav Onkologie A Pneumologie, Nova Ves Plod Plesi, Czech Republic; Institut Bergonie, Bordeaux, France; Haematologisch\/Onkologische Praxis, Hamburg, Germany; University Hospital Leuven, Leuven, Belgium; and Norwegian Radium Hospital, Oslo, Norway."}]},{"given":"J.","family":"Quaresma Albano","sequence":"additional","affiliation":[{"name":"From the Christie Hospital, Manchester, City Hospital, Nottingham, and AstraZeneca, Macclesfield, Cheshire, United Kingdom; Instituto Portugues De Oncologia De Coimbra, Coimbra, Portugal; Odborny Lecebny Ustav Onkologie A Pneumologie, Nova Ves Plod Plesi, Czech Republic; Institut Bergonie, Bordeaux, France; Haematologisch\/Onkologische Praxis, Hamburg, Germany; University Hospital Leuven, Leuven, Belgium; and Norwegian Radium Hospital, Oslo, Norway."}]},{"given":"A.","family":"Aschermannova","sequence":"additional","affiliation":[{"name":"From the Christie Hospital, Manchester, City Hospital, Nottingham, and AstraZeneca, Macclesfield, Cheshire, United Kingdom; Instituto Portugues De Oncologia De Coimbra, Coimbra, Portugal; Odborny Lecebny Ustav Onkologie A Pneumologie, Nova Ves Plod Plesi, Czech Republic; Institut Bergonie, Bordeaux, France; Haematologisch\/Onkologische Praxis, Hamburg, Germany; University Hospital Leuven, Leuven, Belgium; and Norwegian Radium Hospital, Oslo, Norway."}]},{"given":"L.","family":"Mauriac","sequence":"additional","affiliation":[{"name":"From the Christie Hospital, Manchester, City Hospital, Nottingham, and AstraZeneca, Macclesfield, Cheshire, United Kingdom; Instituto Portugues De Oncologia De Coimbra, Coimbra, Portugal; Odborny Lecebny Ustav Onkologie A Pneumologie, Nova Ves Plod Plesi, Czech Republic; Institut Bergonie, Bordeaux, France; Haematologisch\/Onkologische Praxis, Hamburg, Germany; University Hospital Leuven, Leuven, Belgium; and Norwegian Radium Hospital, Oslo, Norway."}]},{"given":"U.R.","family":"Kleeberg","sequence":"additional","affiliation":[{"name":"From the Christie Hospital, Manchester, City Hospital, Nottingham, and AstraZeneca, Macclesfield, Cheshire, United Kingdom; Instituto Portugues De Oncologia De Coimbra, Coimbra, Portugal; Odborny Lecebny Ustav Onkologie A Pneumologie, Nova Ves Plod Plesi, Czech Republic; Institut Bergonie, Bordeaux, France; Haematologisch\/Onkologische Praxis, Hamburg, Germany; University Hospital Leuven, Leuven, Belgium; and Norwegian Radium Hospital, Oslo, Norway."}]},{"given":"I.","family":"Vergote","sequence":"additional","affiliation":[{"name":"From the Christie Hospital, Manchester, City Hospital, Nottingham, and AstraZeneca, Macclesfield, Cheshire, United Kingdom; Instituto Portugues De Oncologia De Coimbra, Coimbra, Portugal; Odborny Lecebny Ustav Onkologie A Pneumologie, Nova Ves Plod Plesi, Czech Republic; Institut Bergonie, Bordeaux, France; Haematologisch\/Onkologische Praxis, Hamburg, Germany; University Hospital Leuven, Leuven, Belgium; and Norwegian Radium Hospital, Oslo, Norway."}]},{"given":"B.","family":"Erikstein","sequence":"additional","affiliation":[{"name":"From the Christie Hospital, Manchester, City Hospital, Nottingham, and AstraZeneca, Macclesfield, Cheshire, United Kingdom; Instituto Portugues De Oncologia De Coimbra, Coimbra, Portugal; Odborny Lecebny Ustav Onkologie A Pneumologie, Nova Ves Plod Plesi, Czech Republic; Institut Bergonie, Bordeaux, France; Haematologisch\/Onkologische Praxis, Hamburg, Germany; University Hospital Leuven, Leuven, Belgium; and Norwegian Radium Hospital, Oslo, Norway."}]},{"given":"A.","family":"Webster","sequence":"additional","affiliation":[{"name":"From the Christie Hospital, Manchester, City Hospital, Nottingham, and AstraZeneca, Macclesfield, Cheshire, United Kingdom; Instituto Portugues De Oncologia De Coimbra, Coimbra, Portugal; Odborny Lecebny Ustav Onkologie A Pneumologie, Nova Ves Plod Plesi, Czech Republic; Institut Bergonie, Bordeaux, France; Haematologisch\/Onkologische Praxis, Hamburg, Germany; University Hospital Leuven, Leuven, Belgium; and Norwegian Radium Hospital, Oslo, Norway."}]},{"given":"C.","family":"Morris","sequence":"additional","affiliation":[{"name":"From the Christie Hospital, Manchester, City Hospital, Nottingham, and AstraZeneca, Macclesfield, Cheshire, United Kingdom; Instituto Portugues De Oncologia De Coimbra, Coimbra, Portugal; Odborny Lecebny Ustav Onkologie A Pneumologie, Nova Ves Plod Plesi, Czech Republic; Institut Bergonie, Bordeaux, France; Haematologisch\/Onkologische Praxis, Hamburg, Germany; University Hospital Leuven, Leuven, Belgium; and Norwegian Radium Hospital, Oslo, Norway."}]}],"member":"233","reference":[{"key":"R1-113280","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/89.11.747"},{"key":"R2-113280","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.18.1371"},{"key":"R3-113280","unstructured":"Wakeling AE, Dukes M, Bowler J: A potent specific pure antioestrogen with clinical potential. Cancer Res 51: 3867,1991-3873,"},{"key":"R4-113280","doi-asserted-by":"publisher","DOI":"10.1023\/A:1017255417749"},{"key":"R5-113280","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/87.10.746"},{"key":"R6-113280","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)91156-1"},{"key":"R7-113280","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-9776(97)90571-3"},{"key":"R8-113280","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.10.058"},{"key":"R9-113280","doi-asserted-by":"publisher","DOI":"10.2307\/2530288"},{"key":"R10-113280","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.3.570"},{"key":"R11-113280","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.974"},{"key":"R12-113280","unstructured":"Buzdar A, Nabholtz JM, Robertson JFR: Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer (ABC) in postmenopausal (PM) women: Combined analysis from two identically designed multicenter trials. Proc Am Soc Clin Oncol 19: 154a,2000 (abstr 609D)"},{"key":"R13-113280","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.22.3758"},{"key":"R14-113280","unstructured":"Milla-Santos A, Milla L, Rallo L, et al: Anastrozole vs tamoxifen in hormone-dependent advanced breast cancer: A phase II randomized trial. Breast Cancer Res Treat 64: 54,2000 (abstr)"},{"key":"R15-113280","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(96)00032-9"},{"key":"R16-113280","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(20000501)88:9<2047::AID-CNCR10>3.0.CO;2-E"},{"key":"R17-113280","doi-asserted-by":"crossref","unstructured":"Pyrohnen S, Valavaara R, Vuorinen J, et al: High dose toremifene in advanced breast cancer resistant to or relapsed during tamoxifen treatment. Breast Cancer Res Treat 56: 133,1999-143,","DOI":"10.1023\/A:1006250213357"},{"key":"R18-113280","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.2.345"},{"key":"R19-113280","doi-asserted-by":"publisher","DOI":"10.1159\/000226637"},{"key":"R20-113280","unstructured":"Buzdar AY, O\u2019Shaugnessy J, Hudis C, et al: Preliminary results of a randomized double-blind phase II study of the selective estrogen receptor modulator (SERM) arzoxifene (AZ) in patients (Pts) with locally advanced or metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 20: 45a,2001 (abstr 178)"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2002.10.057","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T19:39:00Z","timestamp":1682365140000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2002.10.057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,8,15]]},"references-count":20,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2002,8,15]]}},"alternative-id":["10.1200\/JCO.2002.10.057"],"URL":"https:\/\/doi.org\/10.1200\/jco.2002.10.057","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,8,15]]}}}